211 related articles for article (PubMed ID: 20133534)
1. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients.
LaMarr B; Valdez C; Driscoll K; Ryan M
Am J Health Syst Pharm; 2010 Feb; 67(4):290-4. PubMed ID: 20133534
[TBL] [Abstract][Full Text] [Related]
2. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.
Cooke CE; Fatodu H
J Manag Care Pharm; 2006 Oct; 12(8):649-55. PubMed ID: 17269843
[TBL] [Abstract][Full Text] [Related]
3. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
4. An electronic tool to aid community pharmacists in optimizing care for persons with diabetes.
Williams SP; Nunemacher C; Holland C; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S136-S140.e4. PubMed ID: 31248846
[TBL] [Abstract][Full Text] [Related]
5. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.
Rosen AB; Karter AJ; Liu JY; Selby JV; Schneider EC
J Gen Intern Med; 2004 Jun; 19(6):669-75. PubMed ID: 15209606
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
Robles NR; Romero B; Fernandez-Carbonero E; Sánchez-Casado E; Cubero JJ
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
[TBL] [Abstract][Full Text] [Related]
7. Community pharmacist outreach program directed at physicians treating congestive heart failure.
Turner CJ; Parfrey P; Ryan K; Miller R; Brown A
Am J Health Syst Pharm; 2000 Apr; 57(8):747-52. PubMed ID: 10786260
[TBL] [Abstract][Full Text] [Related]
8. Association of Albuminuria Levels With the Prescription of Renin-Angiotensin System Blockade.
Qiao Y; Shin JI; Chen TK; Sang Y; Coresh J; Vassalotti JA; Chang AR; Grams ME
Hypertension; 2020 Dec; 76(6):1762-1768. PubMed ID: 32981368
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.
Coleman CI; Makanji S; Kluger J; White CM
Ann Pharmacother; 2007 Mar; 41(3):433-7. PubMed ID: 17341525
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
11. Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review.
Horning KK; Hoehns JD; Doucette WR
J Manag Care Pharm; 2007; 13(1):28-36. PubMed ID: 17269834
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
McCall KL; Craddock D; Edwards K
Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
[TBL] [Abstract][Full Text] [Related]
13. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age.
Martin U; Foreman MA; Travis JC; Casson D; Coleman JJ
J Clin Pharm Ther; 2008 Oct; 33(5):507-11. PubMed ID: 18834365
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic.
Bhat S; Kansal M; Kondos GT; Groo V
Ann Pharmacother; 2018 Aug; 52(8):724-732. PubMed ID: 29463107
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
Gadzhanova S; Roughead EE; Bartlett LE
Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
[TBL] [Abstract][Full Text] [Related]
16. Pharmacist-driven renal medication dosing intervention in a primary care patient-centered medical home.
Barnes KD; Tayal NH; Lehman AM; Beatty SJ
Pharmacotherapy; 2014 Dec; 34(12):1330-5. PubMed ID: 25346347
[TBL] [Abstract][Full Text] [Related]
17. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
18. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC
Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570
[TBL] [Abstract][Full Text] [Related]
19. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
